Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kairos Pharma (KAPA) Research & Development (2024 - 2025)

Historic Research & Development for Kairos Pharma (KAPA) over the last 2 years, with Q2 2025 value amounting to $496000.0.

  • Kairos Pharma's Research & Development rose 68730.16% to $496000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $1.2 million, marking a year-over-year change of. This contributed to the annual value of $414000.0 for FY2024, which is 40487.8% up from last year.
  • According to the latest figures from Q2 2025, Kairos Pharma's Research & Development is $496000.0, which was up 68730.16% from $493000.0 recorded in Q1 2025.
  • In the past 5 years, Kairos Pharma's Research & Development ranged from a high of $496000.0 in Q2 2025 and a low of $14000.0 during Q3 2024